MA31397B1 - Sels de [4(-(6-fluoro-7-méthylamino-2, 4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phényl]-5-chloro-thiophén-2-yl-sulfonylurée, formes et procédés qui leur sont associés - Google Patents
Sels de [4(-(6-fluoro-7-méthylamino-2, 4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phényl]-5-chloro-thiophén-2-yl-sulfonylurée, formes et procédés qui leur sont associésInfo
- Publication number
- MA31397B1 MA31397B1 MA32376A MA32376A MA31397B1 MA 31397 B1 MA31397 B1 MA 31397B1 MA 32376 A MA32376 A MA 32376A MA 32376 A MA32376 A MA 32376A MA 31397 B1 MA31397 B1 MA 31397B1
- Authority
- MA
- Morocco
- Prior art keywords
- salts
- thrombosis
- diphenylhydro
- diphenoxo
- quinazolin
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 229940100389 Sulfonylurea Drugs 0.000 title 1
- 208000007536 Thrombosis Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000007466 Purinergic P2 Receptors Human genes 0.000 abstract 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 abstract 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92732807P | 2007-05-02 | 2007-05-02 | |
| PCT/US2008/062584 WO2008137809A2 (en) | 2007-05-02 | 2008-05-02 | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31397B1 true MA31397B1 (fr) | 2010-05-03 |
Family
ID=39651344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32376A MA31397B1 (fr) | 2007-05-02 | 2009-11-26 | Sels de [4(-(6-fluoro-7-méthylamino-2, 4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phényl]-5-chloro-thiophén-2-yl-sulfonylurée, formes et procédés qui leur sont associés |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20090042916A1 (enExample) |
| EP (1) | EP2076510A2 (enExample) |
| JP (1) | JP2010526105A (enExample) |
| KR (1) | KR20100020455A (enExample) |
| CN (1) | CN101720324A (enExample) |
| AU (1) | AU2008247457A1 (enExample) |
| BR (1) | BRPI0810800A2 (enExample) |
| CA (1) | CA2686221A1 (enExample) |
| CO (1) | CO6241155A2 (enExample) |
| EA (1) | EA200901474A1 (enExample) |
| EC (1) | ECSP099779A (enExample) |
| GT (1) | GT200900282A (enExample) |
| IL (1) | IL201829A0 (enExample) |
| MA (1) | MA31397B1 (enExample) |
| MX (1) | MX2009011836A (enExample) |
| TN (1) | TN2009000452A1 (enExample) |
| WO (1) | WO2008137809A2 (enExample) |
| ZA (1) | ZA200907493B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101423483B1 (ko) * | 2005-11-03 | 2014-07-28 | 포톨라 파마슈티컬스, 인코포레이티드 | 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법 |
| US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| WO2011006169A1 (en) | 2009-07-10 | 2011-01-13 | Portola Pharmaceuticals, Inc. | Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2 |
| US20130165459A1 (en) * | 2010-01-12 | 2013-06-27 | Norvartis Pharma Ag | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
| WO2011137459A1 (en) | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
| EP2646434B1 (en) * | 2010-12-03 | 2019-05-15 | Portola Pharmaceuticals, Inc. | Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof |
| CN106777526B (zh) * | 2016-11-25 | 2020-05-01 | 江苏大学 | 基于遗传算法的高温高压离心式叶轮多学科优化方法 |
| US10933096B2 (en) | 2017-12-22 | 2021-03-02 | Aesthetics Biomedical, Inc. | Biologic preserving composition and methods of use |
| WO2019126557A1 (en) * | 2017-12-22 | 2019-06-27 | Aesthetics Biomedical, Inc. | Biologic preserving composition and methods of use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3847925A (en) * | 1971-07-15 | 1974-11-12 | En Nom Collectif Science Et Ci | Benzenesulfonyl semicarbazides |
| DE3134780A1 (de) * | 1981-09-02 | 1983-03-10 | Hoechst Ag, 6000 Frankfurt | "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung" |
| US4720450A (en) * | 1985-06-03 | 1988-01-19 | Polaroid Corporation | Thermal imaging method |
| US5314902A (en) * | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
| US6160000A (en) * | 1996-12-23 | 2000-12-12 | Merck & Co., Inc. | Antidiabetic agents based on aryl and heteroarylacetic acids |
| US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| JP4574100B2 (ja) * | 2000-02-04 | 2010-11-04 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 血小板ａｄｐレセプターインヒビター |
| ATE502928T1 (de) * | 2000-11-01 | 2011-04-15 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
| US6824790B2 (en) * | 2002-01-09 | 2004-11-30 | Enzrel Inc. | Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds |
| US20040242658A1 (en) * | 2003-01-08 | 2004-12-02 | Dr. Reddy's Laboratories Limited | Amorphous form of rosiglitazone maleate and process for preparation thereof |
| AU2004278030C1 (en) * | 2003-10-03 | 2010-12-02 | Portola Pharmaceuticals, Inc. | 2,4-Dioxo-3-quinazolinylaryl sulfonylureas |
| KR101423483B1 (ko) * | 2005-11-03 | 2014-07-28 | 포톨라 파마슈티컬스, 인코포레이티드 | 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법 |
| KR20100029746A (ko) * | 2007-05-02 | 2010-03-17 | 포톨라 파마슈티컬스, 인코포레이티드 | 직접 작용하는 가역적인 ｐ2ｙ12 억제제의 정맥내 및 경구 투여 |
| US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
-
2008
- 2008-05-02 CA CA002686221A patent/CA2686221A1/en not_active Abandoned
- 2008-05-02 AU AU2008247457A patent/AU2008247457A1/en not_active Abandoned
- 2008-05-02 CN CN200880022604A patent/CN101720324A/zh active Pending
- 2008-05-02 MX MX2009011836A patent/MX2009011836A/es not_active Application Discontinuation
- 2008-05-02 BR BRPI0810800-5A2A patent/BRPI0810800A2/pt not_active IP Right Cessation
- 2008-05-02 JP JP2010506707A patent/JP2010526105A/ja not_active Withdrawn
- 2008-05-02 EA EA200901474A patent/EA200901474A1/ru unknown
- 2008-05-02 KR KR1020097025052A patent/KR20100020455A/ko not_active Withdrawn
- 2008-05-02 EP EP08747609A patent/EP2076510A2/en not_active Withdrawn
- 2008-05-02 WO PCT/US2008/062584 patent/WO2008137809A2/en not_active Ceased
- 2008-05-02 US US12/114,742 patent/US20090042916A1/en not_active Abandoned
-
2009
- 2009-10-26 ZA ZA200907493A patent/ZA200907493B/xx unknown
- 2009-10-29 IL IL201829A patent/IL201829A0/en unknown
- 2009-10-30 GT GT200900282A patent/GT200900282A/es unknown
- 2009-10-30 TN TNP2009000452A patent/TN2009000452A1/fr unknown
- 2009-11-20 CO CO09132279A patent/CO6241155A2/es not_active Application Discontinuation
- 2009-11-26 MA MA32376A patent/MA31397B1/fr unknown
- 2009-12-02 EC EC2009009779A patent/ECSP099779A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100020455A (ko) | 2010-02-22 |
| CO6241155A2 (es) | 2011-01-20 |
| TN2009000452A1 (en) | 2011-03-31 |
| MX2009011836A (es) | 2010-05-20 |
| CN101720324A (zh) | 2010-06-02 |
| WO2008137809A3 (en) | 2009-01-22 |
| US20090042916A1 (en) | 2009-02-12 |
| ECSP099779A (es) | 2010-01-29 |
| ZA200907493B (en) | 2010-07-28 |
| CA2686221A1 (en) | 2008-11-13 |
| IL201829A0 (en) | 2010-06-16 |
| EP2076510A2 (en) | 2009-07-08 |
| BRPI0810800A2 (pt) | 2014-10-29 |
| AU2008247457A1 (en) | 2008-11-13 |
| GT200900282A (es) | 2010-05-21 |
| JP2010526105A (ja) | 2010-07-29 |
| WO2008137809A2 (en) | 2008-11-13 |
| EA200901474A1 (ru) | 2010-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31397B1 (fr) | Sels de [4(-(6-fluoro-7-méthylamino-2, 4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phényl]-5-chloro-thiophén-2-yl-sulfonylurée, formes et procédés qui leur sont associés | |
| MA31283B1 (fr) | Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse | |
| MA31952B1 (fr) | Pyrrolopyrimidines et pyrrolopyridines | |
| MA54229B1 (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| MA27389A1 (fr) | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. | |
| MA24694A1 (fr) | Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux, et compositions les contenant. | |
| TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
| MA52288B1 (fr) | Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci | |
| MA27329A1 (fr) | Promedicaments a nucleosides 2' et 3' destines a traiter les infections aux flavivirus | |
| TNSN05298A1 (fr) | Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases | |
| MA27483A1 (fr) | Derives d'azole-pyrimidines fondues | |
| MA31766B1 (fr) | Composés organiques | |
| MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
| MA29685B1 (fr) | Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques | |
| MA27559A1 (fr) | Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA29909B1 (fr) | Derives de pyridazine | |
| MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
| MA32009B1 (fr) | Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux | |
| MA28747B1 (fr) | Dérivés de pyridine | |
| MA27775A1 (fr) | Composes organiques | |
| MA29926B1 (fr) | Derives de pyrazine | |
| MA30313B1 (fr) | Amines secondaires en tant qu'inhibiteurs de la renine | |
| MA26717A1 (fr) | Macrolides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA31684B1 (fr) | Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparation |